Use of the butaclamol template in a search for antipsychotic agents with lessened side effects

Publisher Website
Google Scholar
Abstract
A number of molecular similarities between the antipsychotic agents butaclamol and clozapine were noted. Based on the premise that this was a strong indicator of a common mechanism of action(i.e., binding at the antagonist state of the dopamine receptor), a research approach was described. Three simplified analogs of butaclamol which still retained the molecular functionalities of the parent structure were synthesized and tested in the haloperidol receptor assay in calf caudate nuclei. 1-(5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene)-4-tert-butyl-4-piperidine (12a) displaced tritiated haloperidol with an IC50 value of 2.4 nM, as compared to a value of 0.5 nM for butaclamol. When 12a was tested in vivo in rat or in the spiroperidol receptor assay in calf caudate nuclei it was considerably less potent.